Viemed Healthcare US (VMD) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Viemed Healthcare reports a triumphant financial year for 2023, achieving record net revenues of $183 million and a net income increase of 65%, marking its seventh consecutive year of growth. The company also celebrated a significant surge in free cash flow and concluded the year with a strong balance sheet, despite taking on some long-term debt from a substantial acquisition. Looking ahead, Viemed anticipates revenues up to $51 million in the first quarter of 2024, independent of Medicare reimbursement rate adjustments.
For further insights into VMD stock, check out TipRanks’ Stock Analysis page.
